# The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

> **NCT06254521** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Cancer Stage II
- Rectal Cancer Stage III

## Interventions

- **DRUG:** Tislelizumab combined with chemotherapy

## Key facts

- **NCT ID:** NCT06254521
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2024-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254521, "The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06254521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*